T80.82XA Insurance Policy Changes

ICD-10 T80.82XA is officially defined as "Complication of immune effector cellular therapy, initial encounter." code T80.82XA is referenced in 3 tracked payer policy changes from Blue Cross Blue Shield of North Dakota and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code T80.82XA is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Identified Aug 29, 2026High impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota revised its Commercial prior authorization medical drug policies with changes effective October 13, 2026, including expanded indications for Casgevy, Keytruda, Opdivo and other products and updated criteria for many others. Effective September 1, 2026, Navitrux was added to the fosaprepitant policy and Cligavyx was added to the fulvestrant policy, each kept at full parity with its reference product, and the cerebral palsy spasticity exclusion was removed from the Xeomin pediatric upper limb indication. Several products also have HCPCS code changes effective January 1, 2027.
Blue Cross Blue Shield of North Dakota · Effective May 12, 2026Medium impact
Pharmacy Policy Updates
Blue Cross Blue Shield of North Dakota revised many Commercial prior authorization medical drug policies, with revisions effective May 12, 2026. Changes include new indications such as Darzalex SQ for newly diagnosed multiple myeloma, Keytruda IV and SQ for platinum-resistant ovarian cancer, and management of CAR T-cell and lymphocyte engager-related toxicities for several drugs, along with length of authorization updates, new ICD-10 codes and HCPCS code changes.
Aetna · Identified Aug 19, 2026Medium impact
Vedolizumab (Entyvio) (CPB 0885, reviewed 2026-06-30)
Aetna Clinical Policy Bulletin 0885 covers vedolizumab (Entyvio) for commercial medical plans, requires precertification of all Aetna participating providers and members in applicable plan designs, and refers Medicare criteria to the Medicare Part B Criteria. Vedolizumab is considered medically necessary for moderately to severely active Crohn's disease and ulcerative colitis, and for immune checkpoint inhibitor-related toxicity, acute graft versus host disease and CAR T-cell-related toxicity when the listed criteria are met, and it must be prescribed by or in consultation with a gastroenterologist (or a gastroenterologist, hematologist or oncologist for the non-IBD indications). Continuation is considered medically necessary for members who achieve or maintain remission or a positive clinical response, vedolizumab must not be used concomitantly with another biologic or targeted synthetic drug for the same indication, and collagenous colitis, primary sclerosing cholangitis, spondyloarthritis and serum level testing of vedolizumab and antibodies to vedolizumab are considered experimental, investigational or unproven.

Watch T80.82XA

Get one email when a payer policy names T80.82XA, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code T80.82XA?

There are 3 tracked policy changes affecting code T80.82XA, including updates from Blue Cross Blue Shield of North Dakota, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code T80.82XA?

Payers that have issued tracked updates for code T80.82XA include: Blue Cross Blue Shield of North Dakota, Aetna.

How do I get notified when code T80.82XA policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code T80.82XA. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code T80.82XA?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pharmacy Policies Available Online

Pharmacy Policy Updates

Vedolizumab (Entyvio) (CPB 0885, reviewed 2026-06-30)

What insurance policy changes affect code T80.82XA?

Which payers have updated policy for code T80.82XA?

How do I get notified when code T80.82XA policy changes?

Why do payers change policies for code T80.82XA?